The goal of this retrospective observational study is to characterize the clinical features, severity, comorbidities, and treatment patterns of pediatric psoriasis in patients managed in the Costa Rican Social Security System. The main questions it aims to answer are: What are the demographic and clinical characteristics of pediatric psoriasis in Costa Rica? What disease severity profiles, comorbidities, and treatments are observed in routine care? All patients \<18 years with confirmed psoriasis evaluated during the study period will be included. Data will be obtained from electronic health records without intervention or modification of treatment.
Pediatric psoriasis is a chronic immune-mediated inflammatory dermatosis associated with physical, psychosocial, and metabolic comorbidity burden beginning early in life. Epidemiologic and clinical data in Latin American pediatric populations remain limited, particularly in real-world care settings. This study is a retrospective observational characterization of pediatric psoriasis patients managed in the Costa Rican Social Security System. Unlike interventional trials or biologic-specific registries, it analyzes existing clinical records to describe demographic distribution, clinical subtypes, severity (PASI/BSA/DLQI or pediatric indices), comorbidities, and treatment patterns in routine practice. No therapeutic interventions or standardized follow-up are introduced. By capturing real-world pediatric psoriasis presentation and management in Costa Rica, the study provides baseline national evidence distinct from drug-specific or prospective therapeutic studies.
Study Type
OBSERVATIONAL
Enrollment
300
Caja Costarricense del Seguro Social
San José, Provincia de San José, Costa Rica
Treatment patterns used in pediatric psoriasis in real-world clinical practice (topical, phototherapy, systemic, biologic).
Time frame: January 2018- December 2025
Clinical and severity characteristics of pediatric psoriasis, including subtype and severity indices (e.g., PASI/BSA/DLQI or pediatric-adapted measures) documented in routine care.
Time frame: January 2018- December 2025
Comorbidity profile in pediatric psoriasis (e.g., metabolic, cardiovascular risk factors, psoriatic arthritis).
Time frame: January 2018- December 2025
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.